Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Systemic Lupus Erythematosus
- Enrollment Status: Open
- Protocol: M23-699
- Drug: Upadacitinib
- Sponsor: Abbvie
- Description: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active SLE
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Systemic Lupus Erythematosus
- Enrollment Status: Closed
- Protocol: CA42750
- Drug: OBINUTUZUMAB
- Sponsor: Roche
- Description: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Henry Ford Health System – Rheumatology
Primary Coordinator: Jenna Hudy 313-916-9328
- Indication: Systemic Lupus Erythematosus
- Enrollment Status: Open
- Protocol: CVAY736F12301
- Drug: Ianalumab
- Sponsor: Novartis
- Description: A randomized, double-blind, parallel group, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of two regimens of ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 1)
Henry Ford Health System – Rheumatology
Primary Coordinator: Jenna Hudy 313-916-9328
- Indication: Systemic Lupus Erythematosus
- Enrollment Status: Open
- Protocol: ZB012-02-001
- Drug: Oblexelimab
- Sponsor: Zenas BioPharma
- Description: A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluated the efficacy and safety of Obexelimab in patients with systemic lupus eyrthematosus.
Henry Ford Health System – Rheumatology
Primary Coordinator: Jenna Hudy 313-916-9328
- Indication: Systemic Lupus Erythematosus
- Enrollment Status: Open
- Protocol: CA061-1001
- Drug: CAR-T
- Sponsor: Bristol Meyers Squibb
- Description: A Phase 1 Study of CC-97540 in Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM) or Systemic Sclerosis (SSc)